NCT01893801View on ClinicalTrials.gov

Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

April 30, 2016

Study Completion Date

October 1, 2017

Conditions
Stage IV Pancreatic Cancer
Interventions
DRUG

nab-paclitaxel

25 mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle

DRUG

Cisplatin

25mg/m2 (or 50mg/m2) given intravenously (IV) on days 1 and 8 of a 21 day cycle

DRUG

gemcitabine

1000mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle

Trial Locations (3)

18015

Vita Medical Associates, PC, Bethlehem

85260

Scottsdale Health Care, Scottsdale

08901

Rutgers - Cancer Institute of New Jersey (CINJ), New Brunswick

Sponsors
All Listed Sponsors
collaborator

Translational Genomics Research Institute

OTHER

collaborator

Honor Health - Clinical Trials

UNKNOWN

collaborator

Cancer Research and Biostatistics Clinical Trials Consortium

NETWORK

lead

Pancreatic Cancer Research Team

OTHER

NCT01893801 - Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA | Biotech Hunter | Biotech Hunter